Background
Cristina Adriana Popa
2025 IgAN KDIGO guidelines: fresh out of ...

This week, we will discuss the 2025 KDIGO IgAN guidelines. which the shift from supportive care to structured, evidence-based therapy

2025 IgAN KDIGO guidelines: fresh out of press, already aging gracefully
Background
Cristina Adriana Popa
The Protein Pendulum in CKD: supplement or ...

This week, we will discuss an old dilemma in nephrology. To restrict or supplement the proteins? Premise: advanced CKD and dialysis.

The Protein Pendulum in CKD: supplement or restrict?
Background, summary
Brian Rifkin
Chimerism and Immune Tolerance: Can We Says ...

This week, we will discuss the use of creating chimeras to induce immune tolerance and its potential to decrease or eliminate the need for immunosuppression in kidney transplant recipients.

Chimerism and Immune Tolerance: Can We Says Goodbye to Immunosuppression?
Meta
joel topf
NephJC 2025 Fall Pledge Drive

Help keep NephJC a vital, original, and unbiased source of medical education.

NephJC 2025 Fall Pledge Drive
Background, summary
Brian Rifkin
PREVENT, Detect, Treat: What’s New in the 2025 ...

This week, we will discuss the AHA/ACC 2025 hypertension guideline update. Wow, have eight years flown by?

PREVENT, Detect, Treat: What’s New in the 2025 Hypertension Toolkit

Can difelikefalin scratch uremic pruritus?

Can difelikefalin scratch uremic pruritus?

This week we will be discussing the KALM-1 trial which was presented at the Late Breaking and High Impact Trial Session at the recently completed #KidneyWk. It was simultaneously published in the NEJM. Kalm-1 investigated whether difelikefalin, a opioid kappa agonist, decreased uremic pruritus.

Patiromer, spironolactone and resistant hypertension.

Patiromer, spironolactone and resistant hypertension.

The new generation of potassium binders bind potassium but can they improve patient outcomes? These second order questions are starting to be answered. Join us this week to discuss the use of patiromer and spironolactone in patients with resistant hypertension.The AMBER Study

Can We Stop MUC-1 From Mucking Up the Kidney

Can We Stop MUC-1 From Mucking Up the Kidney

Some cases of ADTKD are due to mutations of the MUC-1 gene, one mutation is a frame shift mutation that results in a premature stop codon. which results in accumulation of the abnormally short, and toxic protein MUC-1 fs . The researchers found a small protein, BRD4780, that reroute MUC-1fs to lysosomes, preventing proteinopathy and possibly altering the natural history of the disease.